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Comparing sensitivity to change using the
6-item versus the 17-item Hamilton
depression rating scale in the GUIDED
randomized controlled trial
Boadie W. Dunlop1* , Sagar V. Parikh2, Anthony J. Rothschild3, Michael E. Thase4, Charles DeBattista5,
Charles R. Conway6, Brent P. Forester7, Francis M. Mondimore8, Richard C. Shelton9, Matthew Macaluso10,
Jennifer Logan12, Paul Traxler11, James Li11, Holly Johnson11 and John F. Greden2

Abstract
Background: Previous research suggests that the 17-item Hamilton Depression Rating Scale (HAM-D17) is less sensitive in
detecting differences between active treatment and placebo for major depressive disorder (MDD) than is the HAM-D6 scale,
which focuses on six core depression symptoms. Whether HAM-D6 shows greater sensitivity when comparing two active
MDD treatment arms is unknown.
Methods: This post hoc analysis used data from the intent-to-treat (ITT) cohort (N = 1541) of the Genomics Used to Improve
DEpression Decisions (GUIDED) trial, a rater- and patient-blinded randomized controlled trial. GUIDED compared combinatorial
pharmacogenomics-guided care with treatment as usual (TAU) in patients with MDD. Percent of symptom improvement,
response rate and remission rate from baseline to week 8 were evaluated using both scales. Analyses were performed
for the full cohort and for the subset of patients who at baseline were taking medications predicted by the test to have
moderate or significant gene-drug interactions. A Mokken scale analysis was conducted to compare the homogeneity
of HAM-D17 with that of HAM-D6.
Results: At week 8, the guided-care arm demonstrated statistically significant benefit over TAU when the HAM-D6 (Δ = 4.4%,
p = 0.023) was used as the continuous measure of symptom improvement, but not when using the HAM-D17 (Δ = 3.2%, p =
0.069). Response rates increased significantly for guided-care compared with TAU when evaluated using both HAM-D6 (Δ =
7.0%, p = 0.004) and HAM-D17 (Δ = 6.3%, p = 0.007). Remission rates also were significantly greater for guided-care versus TAU
using both measures (HAM-D6 Δ = 4.6%, p = 0.031; HAM-D17 Δ = 5.5%, p = 0.005). Patients in the guided-care arm who at
baseline were taking medications predicted to have gene-drug interactions showed further increased benefit over TAU at week
8 for symptom improvement (Δ = 7.3%, p = 0.004) response (Δ = 10.0%, p = 0.001) and remission (Δ = 7.9%, p = 0.005) using
HAM-D6. All outcomes showed continued improvement through week 24. Mokken scale analysis demonstrated the
homogeneity and unidimensionality of HAM-D6, but not of HAM-D17, across treatment arms.
Conclusions: The HAM-D6 scale identified a statistically significant difference in symptom improvement between
combinatorial pharmacogenomics-guided care and TAU, whereas the HAM-D17 did not. The demonstrated utility of
pharmacogenomics-guided treatment over TAU as detected by the HAM-D6 highlights its value for future biomarkerguided trials comparing active treatment arms.
(Continued on next page)
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Background
Roughly half of patients with major depressive disorder
(MDD) fail to respond to treatment with an antidepressant medication, and approximately two-thirds fail to
achieve remission [1]. These inadequate outcomes have
sparked great interest in exploring biological subtypes of
depression that correlate with variability in medication
response [2]. Pairing clearly defined subtypes with validated biomarkers such as genetic and epigenetic, proteomic, metabolomic, inflammation, neuroimaging, and
electroencephalography measures might enable more
precise treatment selection and response monitoring.
Genetic variation is an important biological contributor to both MDD development [3, 4] and to treatment
response [5, 6]. On their own, individual gene variants
explain little of the variance in disease risk or outcomes;
rather, clinical manifestation of MDD and treatment response appear to result from the combined effects of
many genes, along with other clinical and environmental
factors. Combinatorial pharmacogenomic tests, which
evaluate the weighted effects of genetic variants to predict which medications may be impacted by gene-drug
interactions, hold promise for aiding patient-specific
treatment selection [7]. Recently, the Genomics Used to
Improve DEpression Decisions (GUIDED) randomized
controlled trial (RCT) reported on the efficacy of using a
combinatorial pharmacogenomic test in medication selection (guided-care), compared with treatment as usual
(TAU), for patients with treatment non-responsive
MDD [8]. This trial differed from traditional drug studies in that patients in both arms received active treatment. GUIDED approached but did not achieve a
statistically significant difference between guided-care versus TAU for its primary outcome, percent symptom improvement at week 8 (p = 0.069; intent-to-treat [ITT]
cohort), as assessed by the Hamilton Depression Rating
Scale, 17-item (HAM-D17). However, significantly more
patients achieved the secondary outcomes, response (p =
0.007) and remission (p = 0.005) at week 8, measured
using HAM-D17, when they received pharmacogenomicsguided care.
The results observed in the GUIDED trial highlight
the challenges in detecting clinically and statistically significant differences in randomized trials when patients
in all study arms receive active treatment. This is especially true in psychiatry, where several well-powered randomized trials comparing active MDD treatments have

failed to show differences in efficacy, including the Sequenced Treatment Alternatives in Depression
(STAR*D) trial [9], the Genome-Based Therapeutic
Drugs for Depression (GENDEP) trial [10], and the
Combining Medications to Enhance Depression Outcomes COMED trial [11]. Lack of significant differences
in efficacy extends even to large trials that compare psychotherapy, antidepressant medications, or their combination [12, 13]. Such equivalent outcomes, despite the
treatments’ distinct mechanisms, raise the possibility
that the assessment metrics used are flawed [14].
The Hamilton Depression Rating Scale (HAM-D) is
the most widely used outcome measure in MDD clinical
trials, with the 17-item version (HAM-D17) originally
published in 1960, serving as the standard [15, 16]. Over
the past four decades, however, researchers have raised
concerns about the ability of the HAM-D17 scale to assess accurately the severity of and change in depression
symptoms [17–19]. Factor analyses of HAM-D17 have
determined that the scale is not a unidimensional measure of depression severity but rather consists of two to
eight symptom factors [20]. Although multidimensionality in a scale is useful for detecting a broad array of clinical features, a multidimensional (or multifactorial) scale
may reduce the ability to detect change over time, because some factors may not adequately distinguish
groups when valid differences exist [21]. The ability to
scale appropriately with illness severity is a fundamental
aspect of construct validity. Medication side effects may
affect some factors on multidimensional scales more
than others, potentially producing total score changes
that do not align with changes in core depressive symptoms [22, 23]. In studies such as GUIDED that allow
concomitant treatments (e.g., sedative hypnotics for insomnia and anxiety in conjunction with antidepressant
medication), assessing efficacy with HAMD-17 becomes
even more problematic, as the uncontrolled additional
medications can result in score changes unrelated to
antidepressant treatment.
To address these shortcomings, researchers developed
abbreviated, more focused versions of HAM-D17 [24]. Of
these, the most widely used is the six-item subscale of
HAM-D17, known as the HAM-D6 or melancholia subscale [23, 25]. The HAM-D6 scale is specific to the core depressive symptoms of depressed mood, guilt, work and
activities, psychomotor retardation, psychic anxiety, and
general somatic symptoms (energy and physical pain), and
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it is unidimensional [26]. HAM-D17 symptoms omitted
from the HAM-D6 scale include suicidal thoughts, initial
insomnia, middle insomnia, late insomnia, psychomotor
agitation, somatic anxiety, gastrointestinal symptoms [appetite], sexual disturbances, hypochondriasis [somatization],
insight, and weight loss. The HAM-D6 scale correlates better with the Clinical Global Impressions Scale-Severity than
does the HAM-D17 scale, particularly among more severely
ill patients [21]. It has repeatedly demonstrated greater effect sizes for second-generation antidepressants than has
HAM-D17, as well as similar effect sizes for medications
that have sedating side effects, such as TCAs and mirtazapine [27–29].
This post hoc analysis of GUIDED trial data evaluated
whether the HAM-D6 scale showed significant differences in outcomes between patients whose treatment
was guided by combinatorial pharmacogenomic testing
versus TAU. We hypothesized that the more sensitive
and unidimensional HAM-D6 would detect a statistically
significant difference in symptom improvement between
the guided-care and TAU arms, whereas the difference
approached but did not achieve significance (p = 0.069)
using HAM-D17. We also examined whether the statistically significantly higher rates of response and remission
observed using the HAM-D17 scale would be replicated
using HAM-D6.

Methods
Pharmacogenomic testing

All enrolled patients were tested with a combinatorial
pharmacogenomic test (GeneSight Psychotropic,
Assurex Health, Inc., now Myriad Neuroscience, Mason,
OH). At the time of the study, the test evaluated genotypes for 59 alleles and variants across eight genes
(CYP1A2, CYP2C9, CYP2C19, CYP3A4, CYP2B6,
CYP2D6, HTR2A, and SLC6A4) [30]. Using a proprietary
algorithm that weighted the combined influences of individual genotypes on each of 38 medications, a report
was generated that categorized the medications into
three levels of gene-drug interaction: ‘use as directed’
(no detected gene-drug interactions); ‘use with caution’
(moderate gene-drug interactions, i.e., medications may
be effective with dose modification); and ‘use with increased caution and with more frequent monitoring’
(significant gene-drug interactions that may significantly
impact drug safety and/or efficacy) [31].
Study description

The GUIDED trial was a 24-week blinded, randomized, controlled trial that evaluated the utility of combinatorial pharmacogenomic testing in medication selection (guided-care)
compared with TAU for adults with MDD. Unlike traditional drug studies, patients in both study arms received active treatment. The study was performed in primary care
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and psychiatry specialty clinics across 60 U.S. community
and academic sites.
Patients and raters were blinded to study arm. Physicians in TAU were blinded to pharmacogenomic test results. The study protocol was approved by the Copernicus
Group independent review board (INC1-14-012) and conducted in accordance with the principles of the Declaration of Helsinki and its amendments. All patients
provided written informed consent for participation. Detailed methods and primary analyses for the GUIDED trial
have been described previously [8]. Methods relevant to
the current analysis are summarized here.
Prior to the baseline visit, patients were randomized 1:1
to the guided-care or TAU arm. Active treatment was
provided to patients in both arms, with medications selected based on clinician judgment, informed by the pharmacogenomic test report for the guided-care arm, and
“standard” clinician judgement in the non-guided arm.
Clinicians for patients in the guided-care arm were not required to adhere to the test results in making medication
decisions, and no medications were prohibited.
Patient assessments were performed at week 0 (baseline)
and at the end of weeks 4, 8, 12 and 24. Patients and raters
in both arms were blinded to study arm and pharmacogenomic test results. Clinicians for patients in the TAU arm
were blinded to test results until after completion of the
week 8 visit. Blinding of patients, sites, and physicians was
maintained through week 8. Sites were instructed to unblind patients to their randomization assignment following the week 12 assessment. Because patient unblinding
may have occurred before week 12 assessments were performed, however, only data collected through the week 8
assessment were considered blinded.
Participants

Patients were enrolled if they were diagnosed with
DSM-IV-TR-defined MDD, confirmed by both the selfrated and site-rated 16-item Quick Inventory of Depression Symptomology (QIDS-SR16 and QIDS-C16 ≥ 11) at
screening and baseline, and if they reported an inadequate response within the current depressive episode to
at least one medication included on the pharmacogenomic test report. Key exclusion criteria included significant short-term suicide risk, bipolar disorder, current
delirium or neurocognitive disorder, psychotic disorder
or psychotic symptoms during the current or a previous
depressive episode, a current substance use disorder, or
a significant unstable medical condition.
Statistical analysis

Analyses described herein were conducted using the ITT
cohort, which included all patients who met eligibility
criteria, were randomized to a study arm, and had at
least one post-baseline visit. Outcomes analyses were
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performed for the ITT cohort and separately for the subset of patients who at baseline were taking medications
predicted to have moderate or significant gene-drug interactions (those in the ‘use with caution’ and ‘use with
increased caution and more frequent monitoring’ report
categories). This subset excluded patients who were taking only medications in the ‘use as directed’ category.
The protocol-defined primary efficacy measure for
GUIDED was the HAM-D17 scale, administered by blinded
central raters (MedAvante-ProPhase Inc., Hamilton, NJ). For
this post hoc scale comparison, HAM-D6 scores were derived from the HAM-D17 assessments. These included: item
1, depressed mood; item 2, guilt feelings; item 7, work and
activities; item 8, psychomotor retardation; item 10, psychic
anxiety; and item 13, general somatic symptoms. Items 1, 2,
7, 8, and 10 each were scored from 0 to 4, and item 13 was
scored from 0 to 2, for a maximum possible HAM-D6 score
of 22. For HAM-D17, the maximum possible score was 52.
The primary endpoint was percent symptom improvement from baseline to week 8, and secondary endpoints
were response and remission rates at week 8. Response
was defined as a ≥ 50% decrease in score at week 8 from
baseline and was assessed for both HAM-D17 and
HAM-D6. Remission was defined as having a score of ≤7
for HAM-D17 [32] and ≤ 4 for HAM-D6 [21, 33]. The
durability of pharmacogenomic testing utility was evaluated in the guided-care arm through outcome assessments at weeks 4, 8, 12, and 24.
Identical statistical methods were used for the primary
HAM-D17 analyses and the post hoc HAM-D6 analyses.
A mixed model for repeated measures was used to assess
percent change in symptoms from baseline to week 8. A
generalized linear mixed model was used for separate
analyses of response and remission at week 8. Because
the response and remission outcomes were measured at
both week 4 and week 8, a generalized linear mixed
model (GLMM) was used to account for both withinsubject and between-subject variability over time. Both
the mixed model for repeated measures and the GLMM
included treatment, week, treatment-by-week interaction, baseline HAM-D6 score, and baseline HAM-D6
score-by-week interaction as fixed effects. Binomial distribution with a log-link function was used for the
GLMM model. The pairwise comparisons between the
two treatment arms at week 8 were tested at a significance level of 0.05 (2-sided). Missing values were handled using maximum likelihood method via mixed
models for repeated measures for both symptom improvement and via generalized linear mixed model for
categorical variables – response and remission. Analyses
were performed with SAS software (version 9.4) or JMP
14 (SAS Institute).
An analysis of scalability was performed using the
non-parametric item response theory model developed
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by Mokken [34]. Using this framework, the deviation of
either the HAM-D17 scale or the HAM-D6 scale from a
perfectly homogeneous structure was expressed using
Loevinger’s scalability coefficient (H) [35], a measure of
the extent to which the scale items represented a single
dimension. Loevinger’s coefficient was interpreted as follows: ≥0.5, strong scale homogeneity; 0.40–0.49, moderate but acceptable homogeneity; 0.30–0.39, doubtful
homogeneity; < 0.30, no homogeneity.

Results
Cohort description

At baseline, the ITT cohort included 1541 patients
(guided-care, n = 760; TAU, n = 781). Baseline clinical
characteristics of the cohort are presented in Table 1.
There were no meaningful differences between the two
treatment arms in depression characteristics, HAM-D17
scores or HAM-D6 scores at baseline. At the week 8
time point, the ITT cohort included 1298 patients
(guided-care, n = 621; TAU, n = 677).
Symptom improvement, response and remission: HAM-D6
versus HAM-D17

At week 8, there was a 28.3% decrease in HAM-D6 scores
from baseline in the guided-care arm, compared with a
23.9% decrease in the TAU arm (Fig. 1). This difference in
mean percent symptom improvement between arms was
statistically significant (Δ = 4.4%, p = 0.023) compared to that
reported previously using the HAM-D17 scale (Δ = 3.2%,
p = 0.069). The response rate at 8 weeks among patients in
the guided-care arm (29.6%) similarly showed a significant
increase over TAU (22.5%) using HAM-D6 (Δ = 7.0%, p =
0.004) (Fig. 1). The percent difference between study arms
also was statistically significant for HAM-D17 (Δ = 6.3%, p =
0.007). Remission rates at week 8 favored pharmacogenomicsguided treatment (20.8%) versus TAU (16.2%) at week 8 using
HAM-D6 (Fig. 1), and the percent difference between study
arms was statistically significant for HAM-D6 (Δ = 4.6%, p =
0.031). The remission rate in the guided-care versus TAU
arms was significant using the HAM-D17 scale (Δ = 5.4%, p =
0.005). Overall, the results for response rate and remission rate
were similar for both scales.
Patients entering on medications with predicted genedrug interactions

To examine the impact of guided-care versus TAU more
specifically for patients who stand to benefit most from
pharmacogenomic testing, HAM-D6 outcomes were
assessed in the subset of patients who at baseline were prescribed medications predicted by the patient’s test results to
have gene-drug interactions (Fig. 2). At week 8, the mean
percent symptom improvement in the guided-care arm
(28.6%) was significantly greater than that measured in
TAU (21.3%) (Δ = 7.3%, p = 0.004). Response rate in the
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Table 1 Clinical features of the GUIDED intent-to-treat study population at baseline (week 0)
Treatment
Characteristic

TAU (N = 781)

Guided-Care (N = 760)

Total (N = 1541)

Mean (SD)

20.74 (4.86)

20.49 (4.84)

20.62 (4.85)

Min, Max

6.0, 35.0

4.0, 37.0

4.0, 37.0

None (0–7)

5 (0.6)

6 (0.8)

11 (0.7)

Mild (8–13)

46 (5.9)

45 (5.9)

91 (5.9)

Moderate (14–18)

189 (24.2)

209 (27.5)

398 (25.8)

HAM-D17

Depression Category, n (%)

Severe (19–22)

270 (34.6)

241 (31.7)

511 (33.2)

Very Severe (≥ 23)

271 (34.7)

259 (34.1)

530 (34.4)

Mean (SD)

10.90 (2.16)

10.99 (2.11)

10.94 (2.13)

Min, Max

1.0, 17.0

3.0, 18.0

1.0, 18.0

Mean (SD)

3.54 (3.01)

3.45 (3.02)

3.49 (3.01)

Min, Max

1, 34

1, 25

1, 34

General anxiety disorder

104 (13.4)

127 (16.7)

231 (15.0)

Panic disorders/social phobia

112 (14.4)

119 (15.7)

231 (15.0)

Post-traumatic stress disorder

35 (4.5)

41 (5.4)

76 (4.9)

HAM-D6

Failed Medication Trials

Psychiatric Comorbidities, n (%)

SD standard deviation, TAU treatment as usual

guided-care arm (29.5%) also was significantly improved
over TAU (19.5%) (Δ = 10.0%, p = 0.001). Finally, remission
rate was improved for guided-care (22.2%) versus TAU
(14.3%) in these patients (Δ = 7.9%, p = 0.005). Compared
with the outcomes assessed using the HAM-D17 scale in
this subset of patients (Fig. 2) [36], the HAM-D6 scale
showed equal or greater sensitivity to detect differences between guided-care and TAU for all three depression outcomes. In addition, the percent differences between guidedcare and TAU across all three outcomes were substantially
higher in patients predicted to be most impacted by genedrug interactions than were those observed in the full patient cohort using either HAM-D17 or HAM-D6 (Fig. 1).

Scale homogeneity

To assess the dimensionality of the HAM-D17 and
HAM-D6 assessments in the GUIDED ITT cohort, a
Mokken scale analysis was performed. Table 2 shows the
Loevinger’s coefficient of homogeneity (H) at week 8 for
each assessment scale. For the combined treatment
arms, HAM-D17 had a coefficient of 0.30, indicating
that the scale is heterogeneous and multidimensional. In
contrast, HAM-D6 had a coefficient of 0.53 for the combined arms, indicating that the scale is homogeneous
and unidimensional. Similar results were observed for
individual treatment arms.

Durability of response

To evaluate the durability of the guided-care treatment
results, patient HAM-D6 scores in the guided-care arm
were evaluated at time points extending through the end
of the 24-week trial period (Fig. 3). Consistent increases
were observed for all three measured outcomes from
baseline through weeks 4, 8, 12, and 24.

Discussion
This comparative, post hoc analysis of the HAM-D6 and
HAM-D17 depression scales in the GUIDED trial for
MDD treatment found greater sensitivity to differences in
treatment effects with the abbreviated version of the scale.
This result likely is due to the narrower focus of the
HAM-D6 scale, as compared with HAM-D17, for the core
symptoms of depression. Furthermore, although both versions of the scale achieved statistically significant differences for the response and remission outcomes, the
greater differences for symptom improvement seen with
the HAM-D6 scale suggest that HAM-D6 provided a
more precise measure for MDD outcome assessment. This
is supported further by the observation of the high sensitivity of the HAM-D6 scale in the subset of patients who
entered the trial on medications predicted by the pharmacogenomic test to have gene-drug interactions. Mokken
scale analysis further supported the increased homogeneity of HAM-D6 relative to HAM-D17. Altogether, these
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Fig. 1 Outcomes at week 8 for the full patient cohort. The pharmacogenomics guided-care arm (N = 621) was compared with treatment as usual
(TAU) (N = 677). Symptom improvement, response and remission outcomes were evaluated using the HAM-D6 and HAM-D17 depression
rating scales

results mirror those seen in many placebo-controlled
pharmacological trials, wherein the HAM-D17 scale failed
to identify an antidepressant effect, while the HAM-D6
scale did [27].
Although the percent differences in response and
remission rates were generally similar for HAM-D17
and HAM-D6, the slightly lower difference in remission rate between arms (0.8%) as assessed by the
HAM-D6 (Δ = 4.6%) versus the HAM-D17 (Δ = 5.4%)
is of interest. A concern in the field is that the
standard HAM-D17 remission threshold of ≤7 may
be high, capturing many patients who continue to
experience impairment or distress from persisting
symptoms [35, 36]. Thus, low levels of core symptoms, as determined by the standard HAM-D6 remission threshold (≤4), might comprise a more valid
measure for defining the state of clinical remission.
The question of whether the HAM-D6 or the HAMD17 remission threshold better predicts restoration
of function and long-term wellness should be a focus
of future work.

The importance of maximizing signal detection
through use of the most sensitive scale to detect treatment effects is of particularly great importance for comparative effectiveness studies and for biomarker-based
clinical trials, both of which provide active treatment to
all patients [37]. Over the past several decades, adequately
powered MDD trials comparing active treatments, be they
medications or psychotherapies, have found no difference
between treatment arms [9–11]. Notably, all of these large
trials have used either the HAM-D17 scale, the Montgomery-Åsberg Depression Rating Scale (MADRS), or the Quick
Inventory of Depressive Symptomatology-Self-Report
(QIDS-SR) as the efficacy measure, each of which contains
numerous items unrelated to core depression symptoms
captured by the HAM-D6 scale. Trials such as GUIDED that
allow concomitant medications for specific symptoms, such
as sedative hypnotics for anxiety or insomnia, can further diminish the ability to identify a difference between treatment
arms when the outcome measure includes non-core depressive symptoms [38]. Consequently, future randomized trials
applying biomarker-based approaches to treatment selection
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Fig. 2 Outcomes at week 8 for patients taking medications with gene-drug interactions. The pharmacogenomics guided-care arm (n = 357) was
compared with treatment as usual (TAU) (n = 429). Symptom improvement, response and remission outcomes were evaluated using the HAM-D6
and HAM-D17 depression rating scales

for MDD may benefit from using the HAM-D6 or a similar,
more focused symptom scale.
The greater discriminative ability of the HAM-D6
scale also allows for smaller sample sizes to test hypotheses about efficacy [39–41]. Given the greater precision
and numerous advantages of HAM-D6, it is difficult to
justify continued use of the full HAM-D17 scale as the
sole primary outcome measure in MDD treatment trials.
In the future, HAM-D17 could be used to enable historic comparisons of baseline severity among trials, but
Table 2 Mokken scale analysis of homogeneity of HAM-D17
and HAM-D6 scores at week 8
Treatment Arm

N

HAM-D17 (H)

HAM-D6 (H)

Combined

1298

0.30

0.53

Guided-Care

621

0.34

0.56

TAU

677

0.27

0.51

Loevinger’s coefficient (H) values were determined for combined treatment
arms, guided-care and treatment as usual. HAM-D6, Hamilton depression
rating scale, 6-item; HAM-D17, Hamilton depression rating scale, 17-item; TAU
treatment as usual

new study protocols should consider specifying the
HAM-D6 or a similarly more precise assessment of core
symptoms [42, 43] as the primary efficacy variable for
analysis. Administering the shorter version can have the
added benefit of reducing time burdens on clinical trial
participants.
This analysis had several strengths that were inherent
to the GUIDED primary analysis. First, the diversity of
the study cohort mirrors that seen across varied clinical
scenarios for MDD treatment, including clinicians in
both psychiatric specialty and primary care clinics. Second, the study’s two active treatment arms reflect realworld clinical practice and provide a relevant evaluation
of clinical utility. The limitations of the primary
GUIDED analysis also apply to this study [8]. Specifically, the treating clinician was not blinded to study arm,
though this limitation was mitigated somewhat by using
blinded central raters, and by keeping the site raters and
patients blinded to study arm until after week 8. The impact of polypharmacy is another intrinsic limitation;
however, as was discussed in the primary analysis,
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Fig. 3 Durability of improvements in patient outcomes in the pharmacogenomics guided-care study arm. Symptom improvement, response and
remission outcomes were evaluated at week 4 (N = 685), week 8, (N = 621), week 12 (N = 585), and week 24 (N = 522) using the HAM-D6
depression rating scale

confounding effects likely would be equivalent between
study arms. A specific limitation of using the HAM-D6
scale is that it does not assess for some important depressive symptoms, including physical symptoms [24]
and suicide. The routine use of separate, more comprehensive suicide assessments in modern clinical trials of
MDD treatments reduces concern about this limitation.

Conclusion
The results of this analysis are consistent with a substantial body of published evidence showing that HAM-D6,
which is focused more precisely on core depressive symptoms, is more sensitive than HAM-D17 in assessing depression symptom improvement in patients with MDD.
The demonstrated utility of pharmacogenomics-guided
treatment over TAU as detected by the HAM-D6 in the
GUIDED trial highlights its value for future biomarkerguided trials comparing multiple active treatment arms.
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